Boehringer Ingelheim and Re-Vana Therapeutics Announce Strategic Collaboration to Develop Long-Acting Ophthalmic Therapies

License Deal, News, Re-Vana

Boehringer Ingelheim and Re-Vana Therapeutics, a US and UK based developer of ocular therapeutics and ocular drug delivery technologies, today announced a strategic collaboration and license agreement that aims to develop first-in-class extended-release therapies for eye diseases.

The terms of the agreement grant Boehringer Ingelheim target exclusivity, and provide for upfront, development, regulatory and commercial milestone payments to Re-Vana, with total potential deal value exceeding $1 billion for the initial three targets, in addition to royalty payments on net sales.

Santen Launches Ryjunea® in Germany for the Treatment of Pediatric Myopia

News, Sydnexis

Following European Commission approval on June 2, 2025, Santen Pharmaceutical Co., Ltd. (hereinafter Santen) today announced that Ryjunea® (development code: STN1012701), is now available in Germany. Germany is the first market to launch Ryjunea®, with other launches across Europe to follow.
Valuation expectations are rising. If SYD-101 succeeds in both the EU and U.S., Sydnexis could command a biotech valuation in the range of $1.5 billion to $2 billion, based on typical pre-commercial revenue multiples. Investor interest is expected to accelerate in Q4 as FDA decision timelines approach.